Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Research from University of Munster yields new findings on acute myeloid leukemia
February 17th, 2009
" The purpose of the study was to assess the contribution of age and disease variables to the outcome of untreated patients with acute myeloid leukemia (AML) receiving varying intensive induction chemotherapy. Patients and Methods Patients 16 to 85 years of age with primary AML, known karyotype, and uniform postremission chemotherapy enrolled onto two consecutive trials were eligible and were randomly assigned to induction either with a standard-dose ( cytarabine, daunorubicin, and 6-thioguanine) and a high-dose ( cytarabine and mitoxantrone) combination, or with two courses of the high-dose combination," investigators in Munster, Germany report. "Subgroups were defined...
Source: Cancer Weekly (2009-02-17)
|
